Dr. Xu Fei is thechiefphysician ofMedicalOncology in Sun Yat-sen University Cancer Center. She obtained her Bachelor in Medicine (equivalent to MD in the US) at Sun Yat-sen University of Medical Sciences, P. R. China in 2000. She got clinical internship training at the First affiliated hospital of Sun Yat-sen University in 2000 and 2001. Then she joined the Department of Medical Oncology in Sun Yat-sen University Cancer Center in July 2001 and worked to present. She obtained her PHD in Oncology at Sun Yat-sen University in 2011. She studied at Department of Clinical Oncology of the Chinese University of HONG KONG as visiting scholar in 2012 and 2013. She focus on breast cancer treatment and prevention，andhas the National Natural Science Project and the Guangdong Provincial Research Fund Project

Breast Cancer treatment and phase I, II, III Clinical trials；

In vitro and in vivo study of anti-cancer drugs

2000 MD Sun Yat-sen University of medical science, China 

2011 PhD (Oncology) Sun Yat-sen University Cancer Center, China

1.Zhou D, Wu Y, Jiang K, Xu F, Hong R, Wang S. Identification of a risk prediction model for clinical prognosis in HER2 positive breast cancer patients. Genomics. 2021 Nov;113(6):4088-4097. doi: 10.1016/j.ygeno.2021.10.010. Epub 2021 Oct 16. PMID: 34666190.
2.Deng H, Wang L, Wang N, Zhang K, Zhao Y, Qiu P, Qi X, Zhang D, Xu F, Liu J. Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data. BMC Cancer. 2023 Jan 7;23(1):29. doi: 10.1186/s12885-023-10515-z. PMID: 36611131; PMCID: PMC9826585.
3.Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY; South China Breast Cancer Group (SCBCG). Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021 Jan 5;325(1):50-58. doi: 10.1001/jama.2020.23370. Erratum in: JAMA. 2022 May 17;327(19):1929. PMID: 33300950; PMCID: PMC7729589.
4.Hua X, Bi XW, Zhao JL, Shi YX, Lin Y, Wu ZY, Zhang YQ, Zhang LH, Zhang AQ, Huang H, Liu XM, Xu F, Guo Y, Xia W, Hong RX, Jiang KK, Xue C, An X, Zhong YY, Wang SS, Huang JJ, Yuan ZY. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clin Cancer Res. 2022 Feb 15;28(4):637-645. doi: 10.1158/1078-0432.CCR-21-3435. PMID: 34810217; PMCID: PMC9377763.
5.Zhou D, Jiang K, Hong R, Lu Q, Xia W, Li M, Zheng C, Zheng Q, Xu F, Wang S. Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer. Front Oncol. 2021 Nov 11;11:747012. doi: 10.3389/fonc.2021.747012. PMID: 34858823; PMCID: PMC8632540.
6.Lu Q, Lee K, Xu F, Xia W, Zheng Q, Hong R, Jiang K, Zhai Q, Li Y, Shi Y, Yuan Z, Wang S. Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center. Cancer Commun (Lond). 2020 May;40(5):222-233. doi: 10.1002/cac2.12029. Epub 2020 May 11. PMID: 32390331; PMCID: PMC7238669.
7.Wang L, Lu Q, Jiang K, Hong R, Wang S, Xu F. BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review. Oncol Res Treat. 2022;45(1-2):54-61. doi: 10.1159/000520453. Epub 2021 Nov 24. PMID: 34818649; PMCID: PMC8985016.
8.An X, Lei X, Huang R, Luo R, Li H, Xu F, Yuan Z, Wang S, de Nonneville A, Gonçalves A, Houvenaeghel G, Li J, Xue C, Shi Y. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature. Cancer. 2020 Aug 15;126 Suppl 16:3837-3846. doi: 10.1002/cncr.32878. PMID: 32710666.
9.Hong R, Xia W, Wang L, Lee K, Lu Q, Jiang K, Li S, Yu J, Wei J, Tang W, Zhou D, An X, Huang J, Xue C, Bi X, Shi Y, Yuan Z, Xu F, Wang S. Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. Cancer Commun (Lond). 2021 Feb;41(2):171-182. doi: 10.1002/cac2.12135. Epub 2021 Feb 2. PMID: 33528890; PMCID: PMC7896747.
10.Zhang K, Jiang K, Hong R, Xu F, Xia W, Qin G, Lee K, Zheng Q, Lu Q, Zhai Q, Wang S. Identification and characterization of critical genes associated with tamoxifen resistance in breast cancer. PeerJ. 2020 Dec 4;8:e10468. doi: 10.7717/peerj.10468. PMID: 33335811; PMCID: PMC7720728.
11.Zhang K, Hong R, Kaping L, Xu F, Xia W, Qin G, Zheng Q, Lu Q, Zhai Q, Shi Y, Yuan Z, Deng W, Chen M, Wang S. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer. Cancer Lett. 2019 Apr 10;447:130-140. doi: 10.1016/j.canlet.2019.01.005. Epub 2019 Jan 21. PMID: 30677445.
12.Jiang K, Xia W, Hong R, Xu F, Zheng Q, Lu Q, Lee K, Li Y, Zhai Q, Shi Y, Yuan Z, Wang S. Local treatment for liver oligometastases in breast cancer patients: identification of prognostic factors and exploration of appropriate treatment strategy. Transl Cancer Res. 2020 Feb;9(2):1225-1234. doi: 10.21037/tcr.2019.12.93. PMID: 35117467; PMCID: PMC8798212.

13.Lee K, Zheng Q, Lu Q, Xu F, Qin G, Zhai Q, Hong R, Chen M, Deng W, Wang S. CPSF4 promotes triple negative breast cancer metastasis by upregulating MDM4. Signal Transduct Target Ther. 2021 May 19;6(1):184. doi: 10.1038/s41392-021-00565-9. PMID: 34006850; PMCID: PMC8131696.

Updated by International Office, Sun Yat-sen University Cancer Center